Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Mitogen-activated protein kinase 14 | ||
| Ligand | BDBM50175753 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_328206 (CHEMBL863945) | ||
| IC50 | 3.8±n/a nM | ||
| Citation |  Bao, J; Hunt, JA; Miao, S; Rupprecht, KM; Stelmach, JE; Liu, L; Ruzek, RD; Sinclair, PJ; Pivnichny, JV; Hop, CE; Kumar, S; Zaller, DM; Shoop, WL; O'neill, EA; O'keefe, SJ; Thompson, CM; Cubbon, RM; Wang, R; Zhang, WX; Thompson, JE; Doherty, JB p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg Med Chem Lett16:64-8 (2005) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Mitogen-activated protein kinase 14 | |||
| Name: | Mitogen-activated protein kinase 14 | ||
| Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta | ||
| Type: | Serine/threonine-protein kinase | ||
| Mol. Mass.: | 41286.76 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | Q16539 | ||
| Residue: | 360 | ||
| Sequence: |
| ||
| BDBM50175753 | |||
| n/a | |||
| Name | BDBM50175753 | ||
| Synonyms: | (2R)-2-(4-(5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-2-oxo-1,2-dihydroquinolin-7-yl)piperidin-1-yl)propanoic acid | CHEMBL200018 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C29H24Cl3FN2O3 | ||
| Mol. Mass. | 573.87 | ||
| SMILES | C[C@@H](N1CCC(CC1)c1cc(-c2ccc(F)cc2Cl)c2ccc(=O)n(-c3c(Cl)cccc3Cl)c2c1)C(O)=O |wD:1.0,(2.98,-33.84,;2.98,-35.38,;1.65,-36.15,;1.65,-37.69,;.32,-38.46,;-1.02,-37.69,;-1.03,-36.15,;.31,-35.38,;-2.35,-38.46,;-2.35,-40.01,;-3.69,-40.79,;-3.68,-42.32,;-5.02,-43.09,;-5.02,-44.63,;-3.69,-45.4,;-3.69,-46.94,;-2.35,-44.62,;-2.35,-43.09,;-1.02,-42.31,;-5.02,-40.02,;-6.35,-40.79,;-7.69,-40.02,;-7.69,-38.47,;-9.02,-37.7,;-6.35,-37.7,;-6.35,-36.17,;-7.68,-35.4,;-9.01,-36.18,;-7.68,-33.87,;-6.34,-33.09,;-5.01,-33.86,;-5.01,-35.4,;-3.68,-36.18,;-5.02,-38.47,;-3.69,-37.7,;4.31,-36.15,;5.65,-35.38,;4.31,-37.69,)| | ||
| Structure | 
| ||